Posted by Michael Wonder on 07 Nov 2019
Little consistency in evidence cited by commercial plans for specialty drug coverage
5 November 2019 - Recently published research indicates wide variation in the evidence that US commercial health plans reported reviewing in their specialty drug coverage policies.
There was little consistency in the numbers or types of studies cited by health plans.
On average, only 15% of health plans’ coverage policies cited the same study evaluating a specific drug for a specific indication.
